This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...

The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.

Johnson & Johnson halted the limited rollout of its Varipulse pulsed field ablation system on Jan. 5 to “investigate the root causes of four reported neurovascular events in the U.S. external ...

Quantum computing stocks are having a tumultuous week, but one fund manager says investors should focus on the long game when ...

Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA ...

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...

Johnson & Johnson said on Wednesday it temporarily paused the rollout of its Varipulse heart device in the United States as ...

Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.

Johnson & Johnson shares are down 3% Wednesday on safety concerns that could dim sales prospects for a new heart device, ...

In that single-arm study, the rate of primary adverse events within 7 days of ablation was 2.9%, with the most common ...

Johnson & Johnson said on Wednesday it has temporarily paused the rollout of its Varipulse heart device in the United States, ...

Piper Sandler analyst Matt O’Brien says Johnson & Johnson’s (JNJ) confirmation that it has temporarily paused the domestic launch of its ...